The T cells in NT-112 are genetically engineered to include disruption of the gene encoding transforming growth factor beta receptor type 2 (TGFBR2) to reduce the immunosuppressive effect of TGF-β in the tumor microenvironment and is currently being investigated in a phase I clinical trial in patients with unresectable, advanced, and/or metastatic KRAS G12D-driven solid tumors (NCT06218914) [226]. Here, KRAS is linked to neoplasm.